RxDoctor Payments Data

Michael McGuire, MD

Family Medicine · Exton, PANPI 1043356066

Payments from drug & device makers

$6,253in general payments, 2019–2025

Across 369 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$873
  • AstraZeneca$640
  • Pfizer$514
  • GSK$381
  • Boehringer Ingelheim$343
  • plus $2K from 46 others

What the payments were for

  • Food & beverage$6,21199%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,253 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$243,907
Medicare patients
529
Services billed
3,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$108,383
OzempicSemaglutide67$74,462
JanuviaSitagliptin Phosphate41$48,660
TrulicityDulaglutide37$46,807
Dupixent SyringeDupilumab11$41,069
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$29,507
MounjaroTirzepatide18$26,809
JardianceEmpagliflozin25$23,172
Xtampza ErOxycodone Myristate22$19,134
FarxigaDapagliflozin Propanediol21$16,825
XareltoRivaroxaban19$13,808
LinzessLinaclotide18$11,612
Aripiprazole44$10,729
JanumetSitagliptin Phos/Metformin Hcl14$9,971
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate35$7,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$514$111,180131 claims
Novo NordiskOzempic$1,109$74,46267 claims
Lilly USA, LLCTrulicity, Mounjaro$125$73,61655 claims
MerckJanuvia, Janumet$109$58,63055 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$381$41,53060 claims
AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort$640$24,11244 claims
Boehringer IngelheimJardiance$343$23,17225 claims
AbbVieLinzess, Synthroid$873$14,08468 claims
Johnson & JohnsonXarelto$15$13,80819 claims
NovartisEntresto$132$7,44511 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$3,747348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Exton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →